UnknownNot Applicable

French HIV-HBV Cohort

France152 participantsStarted 2016-10

Plain-language summary

The overarching purpose of this study is to further understand the reasons for and clinical implications of persistent HBV infection in patients co-infected with HIV and HBV in the era of highly effective antiviral treatment against both viruses.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HBsAg seropositivity for \>6 months (at initial cohort inclusion) * HIV-positive serology confirmed with Western blot (at initial cohort inclusion) * Karnofsky score \>70 (at initial cohort inclusion) * Age ≥18 years old (at initial cohort inclusion) * Completed follow-up in at least one previous study phase of the French HIV-HBV Cohort * Obtained signed written informed consent Exclusion Criteria: * Refusal to participate * Any severe physical, clinical or mental condition preventing participation

What they're measuring

HBV DNA replication

Timeframe: 14 years

HBeAg-seroclearance

Timeframe: 14 years

HBsAg-seroclearance

Timeframe: 14 years

Liver fibrosis (FibroTest)

Timeframe: 14 years

Liver fibrosis (FibroScan)

Timeframe: 14 years

Trial details

NCT IDNCT02889094

SponsorInstitut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-03-31

View on ClinicalTrials.gov More Hepatitis B trials